News From The Journal Of Clinical Investigation: June 23, 2010
Friday, June 25th, 2010We recommend:
Also Included In: Cancer / Oncology ; Cardiovascular / Cardiology ; Transplants / Organ Donations
e-mail to a admirer pressman favorable aspect / compose opinions
METABOLIC DISEASE: Uncovering how the antidiabetic dose glucophage rattling deeds
Metformin is the dose of option for treating individuals with typewrite 2 diabetes . It deeds chiefly by suppressing the product of glucose by the liver-colored. Recent information hint that glucophage suppresses glucose product by the liver-colored by actuating the protein AMPK. However, a squad of researchers, led by Benoit Viollet and Marc Fortez, at Institut Cochin, Paris, has now constitute that glucophage quieten suppresses glucose yield by the liver-colored in mice deficient AMPK. Further psychoanalysis revealed that glucophage in fact elicits its antidiabetic effects in the liver-colored by reduction intracellular levels of ATP (a molecular vim seed). As famed by Morris Birnbaum and Russell Miller, in an concomitant comment, these information get clinical implications because AMPK is considered an attractive mark for the evolution of new drugs to goody typewrite 2 diabetes.
